Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases.
Chalmers
C R
CR
Wilson
D J
DJ
Ward
J
J
Robinson
P J
PJ
Toogood
G J
GJ
Hull
M A
MA
D015179:Colorectal Neoplasms / Q000097:blood / Q000473:pathology*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D043169:Endostatins / Q000097:blood; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000097:blood / Q000098:blood supply* / Q000556:secondary*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D013450:Sulfones / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D052246:Cyclooxygenase 2 Inhibitors; D043169:Endostatins; D007783:Lactones; D013450:Sulfones; D042461:Vascular Endothelial Growth Factor A; C116926:rofecoxib